Abstract
The therapy of inflammatory bowel diseases is currently guided by clinical variables. An escalation of immunosuppressive therapy is required in case of treatment failure. However, clinical remission does not necessarily imply mucosal healing. In parallel to the treatment of rheumatoid arthritis a novel concept is emerging suggesting that an early anti-inflammatory treatment can reduce structural changes in inflammatory bowel diseases. The studies supporting this novel therapeutic strategy that mucosal healing might build the future therapeutic goal will be discussed. In order to adjust the therapy, risk factors indicating a complicated disease course will be identified, resulting in the development of an individual disease course. The benefit of these strategies will be discussed together with therapy-associated complications.
| Translated title of the contribution | What has been confirmed in the treatment of inflammatory bowel disease? |
|---|---|
| Original language | German |
| Pages (from-to) | 1492-1498 |
| Number of pages | 7 |
| Journal | Internist |
| Volume | 51 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2010 |
ASJC Scopus subject areas
- Internal Medicine